AI GRAND ROUNDS

Authors: GEMINI(RESIDENT), GROK(ATTENDING), CHATGPT (EXPERT) & ANUPAM SINGH MD(Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History
A 64-year-old male truck driver from New Delhi is brought to the emergency department by his family because of sudden-onset blurred vision in both eyes, diplopia, frontal headache, and altered mental status that began earlier in the day. He reports no fevers, chills, chest pain, dyspnea, or focal limb weakness. His visual symptoms spontaneously resolved shortly after arrival in the ED, but lethargy and confusion persisted.

Past Medical & Surgical History: History of chronic kidney disease, essential hypertension, and an abdominal aortic aneurysm (AAA) status-post open surgical repair 7 years ago.
Medications: Atenolol (50 mg/day) and Aspirin (75 mg/day).
Personal / Social History: Remote smoking history, drinks 1–3 beers daily. Urine toxicology screen positive for amphetamines and cannabinoids. No recent international travel. No family history of premature coronary artery disease, stroke, or malignancy.

Resident:

Hello, Chief Resident here.

Key Findings:
A 64-year-old male with significant vascular risk factors (HTN, CKD, post-AAA repair) presenting with acute altered mental status, frontal headache, and transient posterior-circulation visual symptoms (bilateral blurred vision, diplopia). Toxicology is positive for amphetamines and cannabinoids.

Differential Diagnoses:
1. Posterior Circulation Ischemia / Top-of-the-Basilar TIA/Stroke (45%): Vascular risk factors and transient brainstem/occipital signs (diplopia, visual blur, confusion) strongly point to vertebrobasilar territory ischemia.
2. Posterior Reversible Encephalopathy Syndrome (PRES) / Hypertensive Encephalopathy (30%): Amphetamine use superimposed on HTN can trigger severe vasospasm/vasogenic edema causing visual disturbances and lethargy.
3. Amphetamine-Induced Neurotoxicity / Acute Substance Intoxication (15%): Sympathomimetic toxicity causing acute altered mental status and transient neurological dysfunction.
4. Metabolic Encephalopathy (10%): Uremic or electrolyte imbalance secondary to underlying CKD exacerbated by acute drug ingestion.

Recommended Next Steps / Tests:
1. Urgent MRI Brain (DWI/FLAIR) with MRA Head/Neck (or NCCT + CTA Head/Neck if MRI unavailable) to rule out basilar artery occlusion or PRES.
2. Immediate Stat Blood Pressure & Capillary Glucose.
3. Comprehensive Metabolic Panel (Electrolytes, BUN, Creatinine, Calcium).
4. 12-lead ECG and continuous telemetry to evaluate for ischemia/arrhythmias.

Attending:

Hello Attending Consultant here

Critique: Solid vascular focus, but underweights amphetamine-triggered PRES/vasospasm and AAA graft complications (e.g., emboli). Tox+ confounds; prioritize BP control and exclude basilar occlusion faster. Add ECG for arrhythmia and CXR/ABG early. MRI first-line is correct but delay risks; CTA bridge if needed. Missing LP consideration if infectious/metabolic unclear.

Top 3 DDx:
1. Top-of-basilar TIA/ischemia (vertebrobasilar)
2. Amphetamine-induced PRES/hypertensive encephalopathy
3. Toxic-metabolic encephalopathy (uremic + sympathomimetic)

Specific points:
1. Stat non-contrast CT + CTA head/neck now (MRI if negative/stable).
2. Continuous arterial-line BP; target <160 systolic, avoid overshoot.
3. Full lytes/ABG/osmolality + troponin/ECG/telemetry.
4. Hold aspirin temporarily; reverse if bleed found.
5. Neurology/stroke alert + ophthalmology for residual fields.
6. Vascular surgery consult re: AAA graft integrity/emboli source.
7. Serial NIHSS + tox clearance monitoring.

Expert:

Hello, Expert Clinician here.

Best current unifying diagnosis: Acute posterior-circulation ischemia—particularly top-of-the-basilar TIA/stroke—until proven otherwise. Bilateral visual disturbance, diplopia, headache, and persistent encephalopathy localize to occipital–thalamic/brainstem circulation; symptom resolution does not exclude ongoing infarction or intermittent basilar occlusion.

Top differentials
1. PRES/hypertensive encephalopathy: Fits headache, visual symptoms, and confusion, especially with CKD, hypertension, and possible stimulant exposure; requires markedly elevated BP and characteristic parieto-occipital vasogenic edema.
2. Amphetamine-associated reversible cerebral vasoconstriction/toxic encephalopathy: Could precipitate vasospasm, ischemia, or PRES. A screening immunoassay alone does not establish causality and may be falsely positive.
3. Toxic-metabolic encephalopathy: CKD-related electrolyte, glucose, or uremic disturbance could explain confusion but less readily explains abrupt diplopia and bilateral visual symptoms.
4. Intracranial hemorrhage: Headache and altered mentation mandate exclusion, though transient focal symptoms are less typical.

Key pivot: Immediate BP/glucose plus neurovascular imaging distinguishes basilar ischemia from hemorrhage or PRES.

Next move: Activate stroke protocol; obtain emergent noncontrast CT and CTA head/neck, followed by MRI DWI/FLAIR if nondiagnostic. Determine last-known-well and thrombectomy/thrombolysis eligibility. Avoid empiric aggressive BP lowering or holding aspirin without imaging.

Teaching pearl: Transient binocular visual symptoms with confusion can be a basilar warning syndrome despite a low NIHSS.

Round 2

User:

Stage 2: Exam + Initial Workup
Physical Examination:
Vitals: Afebrile (36.8°C), BP 145/90 mmHg, HR 72 beats/min (regular), RR 14 breaths/min, SpO2 95% on room air.
General / Neurologic: Lethargic, oriented to person and place but disoriented to time; word-finding difficulty. Cranial nerves intact, visual fields normal, strength 5/5 in all extremities, sensation intact. Ataxic gait with mild dysmetria. Babinski reflex normal.
Cardiovascular / Pulmonary: Scattered bilateral end-inspiratory crackles on lung auscultation. Normal S1/S2 without heart murmur, rub, or gallop.
Skin & Nails: Multiple distinct splinter hemorrhages noted in the nail beds of both hands and the left foot. No other skin rash or petechiae.

Laboratory Investigations:
- Complete Blood Count: Hemoglobin 11.8 g/dL, Platelet count 234,000/µL, WBC count 10,300/µL with a striking differential: 59% Eosinophils (Absolute Eosinophil Count [AEC]: 6,077/µL — profound hypereosinophilia!), 31% neutrophils, 7% lymphocytes, 3% monocytes. Smear shows mature eosinophils with no blast forms.
- Renal & Metabolic Panel: Serum Creatinine 2.5 mg/dL (Baseline unknown), BUN 41 mg/dL. AST 62 U/L, ALT 32 U/L, Alkaline Phosphatase 111 U/L, Total Bilirubin 0.7 mg/dL. Electrolytes and blood glucose normal.
- Urinalysis: 1+ protein, no WBCs, RBCs, or cellular casts. Blood cultures drawn.
- Electrocardiogram & CXR: ECG shows normal sinus rhythm, low voltage in limb leads, and ST depressions with biphasic T waves in leads V3–V6. Chest X-ray reveals bilateral apical pulmonary opacities.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
New findings reveal profound hypereosinophilia (AEC 6,077/µL), multiple splinter hemorrhages, bilateral apical lung opacities, ischemic/low-voltage ECG changes, acute renal impairment (Cr 2.5 mg/dL), and persistent ataxia/encephalopathy.

Differential Diagnoses:
1. Hypereosinophilic Syndrome (HES) with Loeffler Endocarditis (60%): Severe hypereosinophilia causing eosinophil-mediated multi-organ damage—cardiac inflammation/thrombi leading to embolic stroke, splinter hemorrhages, pulmonary infiltrates, and encephalopathy.
2. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (20%): Small-vessel vasculitis causing marked eosinophilia, pulmonary opacities, acute kidney injury, and CNS dysfunction.
3. Cholesterol Crystal Embolization Syndrome (10%): Vascular risk factors, renal failure, splinter hemorrhages, and eosinophilia fit, though AEC >6,000/µL is exceptionally high.
4. Infective / Non-Bacterial Thrombotic Endocarditis (10%): Embolic cause for splinter hemorrhages and focal CNS/renal lesions, secondary to hypercoagulability or underlying cardiac disease.

Recommended Next Steps:
1. Stat Transthoracic/Transesophageal Echocardiogram (evaluating for apical thrombi/endomyocardial fibrosis).
2. Cardiac Troponin I/T and NT-proBNP.
3. Brain MRI with DWI/FLAIR.
4. ANCA panel and FIP1L1-PDGFRA mutation analysis.
5. Urgent High-Dose Corticosteroid Therapy (e.g., IV methylprednisolone) to stem tissue-destructive eosinophilic toxicity.

Attending:

Hello Attending Consultant here

Critique: Strong pivot to HES/Loeffler; correctly prioritizes echo and steroids. Underweights secondary eosinophilia (parasites given Delhi origin) and risks of empiric steroids (strongyloides hyperinfection). Cholesterol emboli still viable post-AAA. ECG changes demand troponin/MRI correlation sooner; ANCA/FIP1L1 alone insufficient without full secondary workup.

Top 3 DDx:
1. Hypereosinophilic syndrome (HES) with Loeffler endocarditis + multi-organ emboli
2. EGPA (eosinophilic vasculitis)
3. Secondary hypereosinophilia (parasitic/tropical or toxin) with cardiac/CNS involvement

Specific points:
1. Urgent TTE/TEE for ventricular thrombi/endomyocardial fibrosis + troponin/BNP.
2. Empiric ivermectin cover before steroids; stool/serology for parasites.
3. Brain MRI DWI + cardiac MRI if stable.
4. Full secondary HES panel (tryptase, B12, flow, CT chest/abd).
5. Hold steroids until infection excluded; then methylpred 1 mg/kg.
6. Vascular surgery re: AAA graft as embolic source.
7. Serial AEC + telemetry for arrhythmias.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Hypereosinophilic syndrome (HES) with eosinophilic myocarditis/Loeffler endocarditis, intracardiac thrombosis, and cerebral embolization. Profound mature hypereosinophilia plus pulmonary infiltrates, ECG abnormalities, renal dysfunction, splinter hemorrhages, and neurologic injury indicates eosinophil-mediated multiorgan disease.

Top differentials
- EGPA: Pulmonary, cardiac, renal, and neurologic involvement fit, but absence of asthma, chronic rhinosinusitis, and typical vasculitic urine sediment argues against it; ANCA may be negative.
- Infective endocarditis: Splinter hemorrhages and embolic CNS disease fit, but afebrile presentation, no murmur, and extreme eosinophilia are atypical. Continue multiple blood cultures.
- Secondary/reactive hypereosinophilia from helminths, drugs, malignancy, or clonal myeloid disease must be excluded.
- Cholesterol embolization: Renal disease and peripheral lesions fit, but repair seven years earlier and AEC >6,000/µL make it less likely.

Key pivot: The AEC transforms this from isolated posterior-circulation ischemia into an organ-threatening systemic eosinophilic disorder.

Next move: Obtain urgent brain MRI, troponin/BNP, and TTE followed by TEE/cardiac MRI for myocarditis or ventricular thrombus. Involve hematology/cardiology and begin systemic glucocorticoids promptly if cardiac/CNS involvement is confirmed or strongly suspected, with empiric ivermectin if Strongyloides exposure is plausible.

Teaching pearl: HES-related cardiac thrombi can cause emboli before fibrosis or a murmur develops.

Round 3

User:

Stage 3: Neuroimaging, Echocardiogram & Biomarkers
Brain Imaging:
- Head CT: Cerebral atrophy and chronic periventricular white-matter changes without acute hemorrhage.
- Brain MRI (DWI): Demonstrated multiple areas of restricted diffusion (hyperintense signals) in the cortex, subcortical white matter, pons, and cerebellum in both cerebral hemispheres — consistent with multiple acute embolic cerebral infarctions! MRA of intracranial vessels was normal.

Clinical Course & Cardiac Evaluation:
- On Hospital Day 2, the patient's confusion and headache completely resolved.
- Transthoracic Echocardiogram (TTE): Normal LV ejection fraction (65%) without valvular vegetations, but revealed a large, mobile, sessile mass attached to the basal septal wall of the left ventricle (LV mural thrombus). Intravenous heparin anticoagulation was initiated.
- Cardiac & Inflammatory Biomarkers: Serum Troponin I 3.90 ng/mL (elevated, normal <0.06), Total CK 288 U/L, CK-MB 24 ng/mL (8.3%). ESR 106 mm/hr (markedly elevated).
- Parasitic & Endocrine Workup: Stool specimens (x2) negative for ova or parasites. Cosyntropin stimulation test: Normal.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Brain MRI confirms acute multifocal cardioembolic strokes. TTE demonstrates a large, mobile left ventricular mural thrombus—the embolic source—alongside elevated Troponin I (3.90 ng/mL) and ESR (106 mm/hr), confirming acute eosinophilic myocarditis.

Differential Diagnoses:
1. Idiopathic Hypereosinophilic Syndrome (HES) / Loeffler Endomyocarditis (70%): Eosinophil-mediated endomyocardial necrosis causing intraventricular thrombosis, acute brain infarcts, and systemic emboli.
2. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (15%): Eosinophilic vasculitis causing multi-organ damage (cardiac, renal, CNS, lungs).
3. Clonal / Myeloproliferative HES (10%): Underlying hematologic driver (e.g., FIP1L1-PDGFRA fusion gene).
4. Secondary / Reactive HES (5%): Unidentified parasitic infection (Toxocara, occult Strongyloides) or paraneoplastic syndrome.

Prioritized Next Steps:
1. Immediate High-Dose Corticosteroids (e.g., IV Methylprednisolone) while continuing anticoagulation (heparin).
2. Molecular/Genetic Testing (FIP1L1-PDGFRA, PDGFRB, FGFR1, JAK2) and Bone Marrow Biopsy to exclude primary myeloproliferative HES.
3. Cardiac MRI to assess the degree of myocardial inflammation and endomyocardial fibrosis.
4. ANCA panel (MPO/PR3) and Serum IgE to evaluate for EGPA.
5. Strongyloides & Toxocara serologies; administer empiric ivermectin during steroid initiation.

Attending:

Hello Attending Consultant here

Critique: Excellent integration of multifocal emboli + LV thrombus + troponin rise as Loeffler. Steroids + heparin now justified; molecular/BMBx correctly prioritized. Under-emphasizes rapid AEC response monitoring and full exclusion of occult infection/malignancy before prolonged steroids. CMR superior to TTE alone for fibrosis extent; ANCA/IgE incomplete without full vasculitis panel.

Top 3 DDx:
1. Idiopathic HES / Loeffler endomyocarditis with cardioemboli
2. EGPA (ANCA-negative possible)
3. Clonal myeloproliferative HES (FIP1L1-PDGFRA+)

Specific points:
1. Start IV methylprednisolone 1 mg/kg immediately + continue UFH (bridge to warfarin).
2. Empiric ivermectin + Strongyloides/Toxocara/filaria serologies.
3. Urgent CMR for thrombus burden/endomyocardial fibrosis + TEE if needed.
4. FIP1L1-PDGFRA/PDGFRB/FGFR1/JAK2 + BMBx/flow/cytogenetics.
5. Full ANCA, IgE, tryptase, B12, CT C/A/P for secondary causes.
6. Serial AEC q12h + telemetry/troponin; neurology for secondary prevention.
7. Hematology consult; hold aspirin pending bleed risk.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Organ-threatening hypereosinophilic syndrome with eosinophilic myocarditis/Loeffler endocarditis, producing a large LV mural thrombus and multifocal cardioembolic cerebral infarctions. Troponin elevation supports myocardial injury despite preserved EF.

Top differentials
- Clonal/myeloid HES: Must be urgently assessed (especially FIP1L1–PDGFRA); mature eosinophils do not exclude it.
- Idiopathic HES: Likely only after secondary and clonal causes are excluded.
- EGPA: Cardiac and pulmonary disease fit, but absent asthma/sinus disease, purpura, and active urine sediment make it less likely; ANCA negativity would not exclude it.
- Secondary eosinophilia from helminths, drugs, or malignancy: still possible. Two negative stool examinations do not exclude Strongyloides.
- Infective endocarditis: Emboli and splinter hemorrhages fit, but no vegetation, fever, or murmur and the extreme eosinophilia argue against it.

Key pivot: Demonstration of both multifocal infarcts across vascular territories and a mobile LV thrombus establishes cardioembolism within a systemic eosinophilic process.

Immediate move: Continue carefully monitored UFH after neurology assessment of hemorrhagic-conversion risk; initiate urgent systemic glucocorticoids, with empiric ivermectin if exposure is plausible. Obtain cardiac MRI, serial troponin/AEC, marrow and molecular studies, and Strongyloides serology.

Teaching pearl: Preserved EF does not exclude severe eosinophilic endomyocardial disease.

Round 4

User:

Stage 4: Tissue Diagnostics & Comprehensive Workup
Specialized Cardiac & Bone Marrow Investigations:
- Cardiac MRI: Perfusion imaging showed delayed gadolinium hyperenhancement of the inferior LV wall, indicative of myocardial fibrosis/inflammation.
- Endomyocardial Biopsy: Histopathology confirmed acute endomyocarditis characterized by extensive myocardial necrosis, inflammatory infiltrates, and intense infiltration with eosinophils and lymphocytes.
- Bone Marrow Aspirate & Biopsy: Normocellular marrow with trilineage hematopoiesis and severe eosinophilic hyperplasia. No blast cells, granulomas, or lymphoid aggregates. Karyotype and flow cytometry normal.

Molecular & Systemic Workup:
- Molecular Genetics: FIP1L1-PDGFRα fusion gene mutation (deletion on chromosome 4q12): NEGATIVE. T-cell receptor (TCR) gene rearrangements: Negative.
- Infectious & Autoimmune Serology: Blood/sputum cultures negative. HIV, Coccidioidomycosis, Strongyloides, Schistosomiasis, and Aspergillosis serologies: Negative. ANA, ANCA (anti-MPO, anti-PR3), and Antiphospholipid antibodies: Negative.
- Gastrointestinal Evaluation: Colonoscopy identified a friable 3-cm cecal mass. Repeat biopsies confirmed a benign tubulovillous adenoma without malignancy. Abdominal/pelvic CT showed no lymphadenopathy or hepatic metastases.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Endomyocardial biopsy confirms acute eosinophilic myocarditis. Extensive systemic workup excludes secondary (parasitic, fungal, autoimmune, neoplastic) and clonal (FIP1L1-PDGFRA, TCR rearrangement, karyotype) etiologies.

Differential Diagnoses:
1. Idiopathic Hypereosinophilic Syndrome (HES) with Loeffler Endomyocarditis (85%): Sustained AEC >1,500/µL with biopsy-proven endomyocardial necrosis, intraventricular thrombus, cerebral cardioemboli, pulmonary, and renal injury, with all reactive and clonal causes ruled out.
2. ANCA-Negative Eosinophilic Granulomatosis with Polyangiitis (10%): Multi-organ involvement fits, but absence of asthma, rhinosinusitis, vasculitic urine sediment, or granulomas on biopsy makes this less probable.
3. Occult Secondary / Paraneoplastic Hypereosinophilia (5%): Highly unlikely given negative infectious, autoimmune, and oncologic workup, and benign histology of the cecal adenoma.

Prioritized Next Steps:
1. High-Dose Corticosteroids: Initiate IV methylprednisolone (1 mg/kg/day) transitioning to oral prednisone taper.
2. Anticoagulation: Continue UFH bridged to Warfarin (target INR 2.0–3.0) for LV thrombus.
3. Steroid-Sparing Therapy: Consider early Mepolizumab (anti-IL-5) or Hydroxyurea if corticosteroid response is incomplete.
4. Polypectomy: Plan endoscopic resection of the cecal tubulovillous adenoma.
5. Follow-up Imaging: Repeat TTE in 4–6 weeks to monitor thrombus resolution.

Attending:

Hello Attending Consultant here

Critique: Biopsy-proven eosinophilic endomyocarditis + exhaustive negative workup correctly seals idiopathic HES/Loeffler. Steroids + AC appropriate; early mepolizumab consideration smart. Underweights serial AEC kinetics, thrombus evolution risk, and need for longer-term cardiac surveillance. Cecal adenoma incidental—defer polypectomy until stable. EGPA remains remote without vasculitis histology.

Top 3 DDx:
1. Idiopathic HES with Loeffler endomyocarditis + cardioemboli
2. ANCA-negative EGPA
3. Occult secondary hypereosinophilia (missed helminth/paraneoplastic)

Specific points:
1. IV methylpred 1 mg/kg now; taper per AEC drop (<500/µL target).
2. Continue UFH→warfarin (INR 2–3); repeat TTE/CMR at 4–6 wk for thrombus/fibrosis.
3. Add mepolizumab early if steroid-dependent or incomplete response.
4. Serial AEC/troponin q12–24h + telemetry.
5. Hematology co-manage; hydroxyurea bridge if needed.
6. Empiric ivermectin complete; no further infection chase.
7. Defer polypectomy; outpatient GI.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Idiopathic hypereosinophilic syndrome (HES) with biopsy-proven eosinophilic endomyocarditis (Loeffler endocarditis), LV mural thrombosis, and multifocal cardioembolic strokes. Pulmonary infiltrates and renal dysfunction likely represent additional eosinophil-mediated organ injury.

Top differentials
- Clonal/myeloid HES: Less likely with normal marrow cytogenetics/flow and negative FIP1L1–PDGFRA, although broader myeloid sequencing may be considered if treatment response is atypical.
- Lymphocytic-variant HES: Unlikely given negative TCR rearrangement and no aberrant lymphoid population.
- ANCA-negative EGPA: Cardiac and pulmonary involvement fit, but no asthma, sinonasal disease, granulomatous vasculitis, or active urinary sediment.
- Secondary eosinophilia: Extensive infectious, drug, autoimmune, and malignancy evaluation is unrevealing. The benign cecal adenoma is likely incidental.

Key pivot: Endomyocardial biopsy proves eosinophil-mediated cardiac injury; negative clonal and secondary evaluations support idiopathic HES.

Most important move: Start high-dose systemic glucocorticoids immediately and track AEC, troponin, ECG, and cardiac function. Continue carefully monitored anticoagulation for the mobile LV thrombus, transitioning to longer-term therapy with repeat echocardiography/CMR. Add mepolizumab if steroid-refractory or dependent.

Teaching pearl: In HES, cardiac necrosis and thrombosis can occur despite preserved ejection fraction.

Round 5

User:

Stage 5: Final Results & Clinical Outcome
Final Diagnosis:
Idiopathic Hypereosinophilic Syndrome (HES) with Eosinophilic Endomyocarditis (Löffler Endocarditis), Left Ventricular Mural Thrombus, Multiple Cerebral & Peripheral Embolic Strokes, and Splinter Hemorrhages.

Pathophysiologic Mechanism:
Eosinophil toxicity (via major basic protein and eosinophil cationic protein) led to endomyocardial inflammation and necrosis, precipitating an LV basal septal mural thrombus. Thrombus fragmentation resulted in embolic cerebral strokes (causing transient diplopia, amaurosis, and confusion) and peripheral microvascular emboli (splinter hemorrhages).

Treatment & Clinical Response:
- High-Dose Corticosteroid Therapy: Initiated oral Prednisone (1 mg/kg/day = 60 mg/day) and anticoagulation (Heparin transitioned to Warfarin + Aspirin).
- Hematologic & Cardiac Response: Eosinophil count dropped precipitously from 5,010/µL to 64/µL within days.
- 2-Week Follow-up Echo: Complete resolution of the left ventricular mural thrombus.
- Long-Term Follow-up: At 1 month, patient was asymptomatic with normal eosinophil counts. Repeat endomyocardial biopsy at 2 months demonstrated completely healed myocarditis with zero residual eosinophils. Cecal tubulovillous adenoma was endoscopically/surgically resected at 10 months. Patient achieved full clinical recovery without residual stroke or cardiac deficits.

Resident:

Hello, Chief Resident here.

Key Findings:
Dramatic resolution of profound hypereosinophilia (AEC 6,077 → 64/µL) following high-dose prednisone, with complete disappearance of the left ventricular mural thrombus at 2 weeks and histologically confirmed resolution of eosinophilic myocarditis on repeat endomyocardial biopsy at 2 months.

Probability-Based Diagnoses:
1. Idiopathic Hypereosinophilic Syndrome (HES) with Löffler Endomyocarditis (95%): Confirmed by endomyocardial biopsy, multi-organ embolic complications, exhaustive exclusion of secondary/clonal causes, and rapid, sustained clinical response to corticosteroids.
2. ANCA-Negative Eosinophilic Granulomatosis with Polyangiitis (EGPA) (3%): Excluded long-term given absence of asthma, sinonasal disease, or vasculitic recurrence.
3. Clonal / Secondary Hypereosinophilia (2%): Effectively ruled out by negative molecular genetics (FIP1L1-PDGFRα), marrow cytogenetics, parasite panels, and sustained remission.

Recommended Long-Term Management Steps:
1. Gradual Prednisone Taper: Monitor serial AEC and troponin to maintain target AEC <500/µL without relapse.
2. Anticoagulation Strategy: Continue Warfarin for 3–6 months with repeat TTE prior to discontinuation.
3. Long-Term Cardiac Surveillance: Periodic TTE or cardiac MRI to screen for late-onset endomyocardial fibrosis.
4. Routine GI Care: Routine surveillance colonoscopy following successfully resected cecal tubulovillous adenoma.

Attending:

Hello Attending Consultant here

Critique: Excellent closure on idiopathic HES/Löffler with biopsy-proven resolution and rapid AEC/thrombus clearance. Taper and AC duration appropriate; underweights lifelong fibrosis surveillance and steroid-sparing thresholds. Adenoma resection timing correct post-stabilization. No need for further clonal chase given sustained remission.

Top 3 DDx:
1. Idiopathic HES with Löffler endomyocarditis + resolved cardioemboli
2. ANCA-negative EGPA (remote)
3. Occult clonal HES (ruled out)

Specific points:
1. Taper prednisone over 3–6 mo targeting AEC <500/µL; add mepolizumab if rebound.
2. Warfarin 3–6 mo then reassess thrombus-free TTE/CMR before stop; lifelong ASA.
3. Serial AEC/troponin q1–3 mo ×1 yr then prn; annual CMR for fibrosis.
4. Hematology co-follow; hydroxyurea reserve only.
5. Echo/ECG at 1/3/6/12 mo for late cardiomyopathy.
6. GI surveillance post-polypectomy per adenoma guidelines.
7. Educate on relapse signs (visual/neuro/cardiac).

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis: Idiopathic hypereosinophilic syndrome with biopsy-proven eosinophilic endomyocarditis (Löffler endocarditis), LV mural thrombosis, and multifocal cerebral/peripheral embolization. Eosinophil granule proteins caused myocardial necrosis and a thrombogenic endocardial surface; thrombus fragmentation produced multiterritorial strokes and splinter hemorrhages.

Residual differentials:
- EGPA: Unlikely without asthma, sinonasal disease, vasculitic histology, ANCA, or active urinary sediment.
- Clonal/lymphocytic HES: Unsupported by marrow, cytogenetic/flow, FIP1L1-PDGFRA, and TCR studies.
- Secondary eosinophilia: Extensive infectious, autoimmune, drug, and malignancy evaluation was negative; the cecal adenoma was benign.

Key pivot: Profound eosinophilia plus multiterritorial infarcts prompted echocardiography, revealing the LV thrombus; myocardial biopsy then established eosinophilic endomyocarditis.

Most important ongoing move: Gradually taper prednisone while monitoring AEC, symptoms, troponin, ECG, and echocardiography. Continue anticoagulation for an individualized period—commonly 3–6 months—and confirm persistent thrombus resolution before stopping. Reassess the need for concomitant aspirin because combined therapy increases bleeding risk. Consider mepolizumab for relapse or steroid dependence.

Teaching pearl: Severe eosinophilic cardiac injury and embolization can occur with normal ejection fraction and no murmur.

Top 15 Takeaways for Clinicians

    Top 15 Takeaways for Clinicians

    1. Marked hypereosinophilia (AEC >1,500/µL) is a critical diagnostic red flag. Unexplained severe eosinophilia warrants urgent systemic evaluation for organ-threatening infiltration, particularly cardiac, neurological, and pulmonary involvement.
    2. Eosinophilic endomyocarditis can occur with normal cardiac ejection fraction. Severe myocardial necrosis, endocardial inflammation, and intraventricular thrombi can develop before global LV systolic dysfunction or heart failure manifests.
    3. Left ventricular mural thrombi in HES are highly thrombogenic. Eosinophil granule proteins (major basic protein, eosinophil cationic protein) induce local endocardial inflammation and thrombosis, creating a high risk for cardioembolic strokes and peripheral emboli.
    4. Splinter hemorrhages are not specific to bacterial endocarditis. Peripheral embolic lesions, including fingernail and toenail splinter hemorrhages, can arise from non-bacterial intracardiac thrombi in Löffler endocarditis.
    5. Transient neurological symptoms can signify multifocal embolic strokes. Transient visual loss or confusion in a patient with HES should prompt immediate brain MRI with diffusion-weighted imaging (DWI) to detect embolic损害.
    6. Echocardiography (TTE/TEE) is mandatory in hypereosinophilic syndromes. Screen all patients with AEC >1,500/µL for intracardiac thrombi, valvular thickening, and endomyocardial fibrosis, even if asymptomatic or without a murmur.
    7. Endomyocardial biopsy provides definitive histological confirmation. Demonstrating heavy subendocardial eosinophilic and lymphocytic infiltration with myocyte necrosis establishes the diagnosis of Löffler endomyocarditis.
    8. Rule out clonal eosinophilia via FIP1L1-PDGFRα fusion testing. Screening for the FIP1L1-PDGFRα deletion (chromosome 4q12) is essential; positive cases respond dramatically to targeted tyrosine kinase inhibitor therapy (imatinib).
    9. Exclude secondary causes of reactive eosinophilia systematically. Thoroughly rule out helminthic infections (e.g., Strongyloides), fungal diseases, drug reactions, autoimmune vasculitides (EGPA), and occult malignancies.
    10. High-dose systemic corticosteroids are the first-line treatment. Prednisone (1 mg/kg/day) rapidly suppresses eosinophil counts, blunts endomyocardial inflammation, and prevents progressive organ destruction.
    11. Empiric anti-helminthic therapy (Ivermectin) prevents hyperinfection. Before initiating high-dose steroids in patients with potential Strongyloides exposure, administer empiric ivermectin to prevent fatal hyperinfection syndrome.
    12. Combine anticoagulation with steroid therapy for LV thrombi. Initiate heparin transitioned to warfarin for intracardiac mural thrombi, monitoring for resolution via repeat echocardiography or cardiac MRI.
    13. Mepolizumab is an effective steroid-sparing biologic in HES. Monoclonal anti-IL-5 antibody therapy (mepolizumab) can be added for steroid-refractory, steroid-dependent, or severe HES relapses.
    14. Monitor serial cardiac biomarkers during steroid tapering. Track AEC, serum troponin, and serial echocardiograms during corticosteroid dose reduction to detect early subclinical endomyocardial reactivation.
    15. Complete histological and anatomical resolution is achievable. Early diagnosis and aggressive dual steroid/anticoagulation therapy can achieve complete dissolution of intracardiac thrombi and total histological clearance of endomyocarditis.